Paraneoplastic syndromes of the CNS

The Lancet Neurology

Volumn 7, Issue 4, 2008, Pages 327-340

  Dalmau, Josep ^a   Rosenfeld, Myrna R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPHYSIN; ANTIGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HU PROTEIN; IMMUNOGLOBULIN; MA2 ANTIGEN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RITUXIMAB; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER STAGING; CENTRAL NERVOUS SYSTEM; CEREBELLUM DEGENERATION; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; CREUTZFELDT JAKOB DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ELECTROENCEPHALOGRAM; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MYASTHENIA GRAVIS; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THYMOMA;

CENTRAL NERVOUS SYSTEM; DIAGNOSTIC IMAGING; HUMANS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 40749109846     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70060-7     Document Type: Review

References (137)

1. Guichard M., and Vignon G. La Polyradiculonéurite cancéreuse métastatique. Le J Médecine de Lyon (1949) 197-207
2. Guichard M., Cabanne F., Tommasi M., and Fayolle J. Polyneuropathies in cancer patients and paraneoplastic polyneuropathies. Lyon Medicale 41 (1956) 309-329
3. Antoine J., and Camdessanche J. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 6 (2007) 75-86
4. Rudnicki S., and Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 23 (2000) 1800-1818
5. Rudnicki S., and Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 18 (2005) 598-603
6. Darnell R., and Posner J. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 33 (2006) 270-298
7. Darnell R., and Posner J. Paraneoplastic syndromes involving the nervous system. N Engl J Med 349 (2003) 1543-1554
8. Pittock S., Kryzer T., and Lennon V. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56 (2004) 715-719
9. Viala K., Behin A., Maisonobe T., et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis?. J Neurol Neurosurg Psychiatry (2007) 10.1136/jnnp.2007.125930 published online Oct 30.
10. Elrington G., Murray N., Spiro S., and Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer: a prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 54 (1991) 764-767
11. Buckley C., and Vincent A. Autoimmune channelopathies. Nat Clin Pract Neurol 1 (2005) 22-33
12. O'Neill J., Murray N., and Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 111 (1988) 577-596
13. Graus F., Lang B., Pozo-Rosich P., Saiz A., Casamitjana R., and Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59 (2002) 764-766
14. Vincent A., Buckley C., Schott J., et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127 (2004) 701-712
15. Liguori R., Vincent A., Clover L., et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124 (2001) 2417-2426
16. Sillevis S., Kinoshita A., De Leeuw B., et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342 (2000) 21-27
17. Zuliani L., Sabater L., Saiz A., Baiges J., Giometto B., and Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology 68 (2007) 239-240
18. Dalmau J., Tuzun E., Wu H., et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61 (2007) 25-36
19. Manto M., Laute M., Aguera M., Rogemond V., Pandolfo M., and Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 61 (2007) 544-551
20. Sommer C., Weishaupt A., Brinkhoff J., et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365 (2005) 1406-1411
21. Albert M., Austin L., and Darnell R. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 47 (2000) 9-17
22. Benyahia B., Liblau R., Merle-Beral H., Tourani J., Dalmau J., and Delattre J. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 45 (1999) 162-167
23. Rousseau A., Benyahia B., Dalmau J., et al. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 71 (2005) 231-236
24. Carpenter E., Vance B., Klein R., Voloschin A., Dalmau J., and Vonderheide R. Functional analysis of CD8(+) T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol (2007) 10.1016/j.jneuroim.2007.10.014 published online Nov 28.
25. Sutton I., Steele J., Savage C., Winer J., and Young L. An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. J Neuroimmunol 150 (2004) 98-106
26. De Giorgio R., Bovara M., Barbara G., et al. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology 125 (2003) 70-79
27. Tanaka K., Tanaka M., Igarashi S., Onodera O., Miyatake T., and Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg 97 (1995) 101-105
28. Smitt P.S., Manley G., and Posner J. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 45 (1995) 1873-1878
29. Carpentier A., Rosenfeld M., Delattre J., Whalen R., Posner J., and Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 4 (1998) 2819-2824
30. Pellkofer H., Schubart A., Hoftberger R., et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain 127 (2004) 1822-1830
31. Dalmau J., Gultekin S., Voltz R., et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 122 (1999) 27-39
32. Uchuya M., Graus F., Vega F., Reñé R., and Delattre J. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 60 (1996) 388-392
33. Graus F., Vega F., Delattre J., et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 42 (1992) 536-540
34. Shams'ili S., Grefkens J., De Leeuw B., et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 126 (2003) 1409-1418
35. Blumenthal D., Salzman K., Digre K., Jensen R., Dunson W., and Dalmau J. Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis. Neurology 67 (2006) 146-149
36. Bernal F., Graus F., Pifarre A., Saiz A., Benyahia B., and Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (Berl) 103 (2002) 509-515
37. Voltz R., Dalmau J., Posner J., and Rosenfeld M. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 51 (1998) 1146-1150
38. Graus F., Delattre J., Antoine J., et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 (2004) 1135-1140
39. Posner J. Neurologic Complications of Cancer (1995), FA Davis Company, Philadelphia
40. Younes-Mhenni S., Janier M., Cinotti L., et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127 (2004) 2331-2338
41. Linke R., Schroeder M., Helmberger T., and Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 63 (2004) 282-286
42. Mathew R., Vandenberghe R., Garcia-Merino A., et al. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology 68 (2007) 900-905
43. Mason W., Graus F., Lang B., et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120 (1997) 1279-1300
44. Peterson K., Rosenblum M., Kotanides H., and Posner J. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42 (1992) 1931-1937
45. Dalmau J., Gonzalez R., and Lerwill M. Case records of the Massachusetts General Hospital: case 4-2007-a 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med 356 (2007) 612-620
46. Rosenfeld M., Eichen J., Wade D., Posner J., and Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 50 (2001) 339-348
47. Yu Z., Kryzer T., Griesmann G., Kim K., Benarroch E., and Lennon V. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49 (2001) 146-154
48. de Andres C., Esquivel A., de Villoria J., Graus F., and Sanchez-Ramon S. Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study. J Neurol Neurosurg Psychiatry 77 (2006) 562-563
49. Choi K., Kim J., Park S., Kim Y., Kim S., and Smitt P. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 77 (2006) 525-528
50. Saiz A., Graus F., Dalmau J., Pifarre A., Marin C., and Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol 46 (1999) 774-777
51. Honnorat J., Saiz A., Giometto B., et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58 (2001) 225-230
52. Rakocevic G., Raju R., Semino-Mora C., and Dalakas M. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology 67 (2006) 1068-1070
53. Giometto B., Marchiori G., Nicolao P., et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 23 (1997) 468-474
54. Verschuuren J., Chuang L., Rosenblum M., et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol (Berl) 91 (1996) 519-525
55. Rojas I., Graus F., Keime-Guibert F., et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55 (2000) 713-715
56. Bernal F., Shams'ili S., Rojas I., et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 60 (2003) 230-234
57. Vernino S., and Lennon V. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 47 (2000) 297-305
58. Chan K., Vernino S., and Lennon V. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 50 (2001) 301-311
59. Bataller L., Sabater L., Saiz A., Serra C., Claramonte B., and Graus F. Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol 56 (2004) 575-579
60. Bataller L., Wade D., Graus F., Stacey H., Rosenfeld M., and Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 62 (2004) 778-782
61. Sabater L., Bataller L., Carpentier A., et al. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J Neurol Neurosurg Psychiatry 77 (2006) 1359-1362
62. Storstein A., Knudsen A., and Vedeler C. Proteasome antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol 165 (2005) 172-178
63. Candler P., Dale R., Griffin S., et al. Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry 77 (2006) 507-512
64. Deconinck N., Scaillon M., Segers V., Groswasser J., and Dan B. Opsoclonus-myoclonus associated with celiac disease. Pediatr Neurol 34 (2006) 312-314
65. Bataller L., Rosenfeld M., Graus F., Vilchez J., Cheung N., and Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 53 (2003) 347-353
66. Sabater L., Gomez-Choco M., Saiz A., and Graus F. BR serine/threonine kinase 2: a new autoantigen in paraneoplastic limbic encephalitis. J Neuroimmunol 170 (2005) 186-190
67. Knudsen A., Bredholt G., Storstein A., Oltedal L., Davanger S., Krossnes B., Honnorat J., and Vedeler C. Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clin Exp Immunol 149 (2007) 16-22
68. Tuzun E., Rossi J., Karner S., Centurion A., and Dalmau J. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. J Neuroimmunol 186 (2007) 177-180
69. Okamoto S., Hirano T., Takahashi Y., Yamashita T., Uyama E., and Uchino M. Paraneoplastic limbic encephalitis caused by ovarian teratoma with autoantibodies to glutamate receptor. Intern Med 46 (2007) 1019-1022
70. Keime-Guibert F., Graus F., Fleury A., et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68 (2000) 479-482
71. Bradley W., Dottino P., and Rahaman J. Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation. Int J Gynecol Cancer (2008) 10.1111/j.1525-1438.2007.01173.x published online Jan 22.
72. Widdess-Walsh P., Tavee J., Schuele S., and Stevens G. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 63 (2003) 187-190
73. David Y., Warner E., Levitan M., Sutton D., Malkin M., and Dalmau J. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin: a case report. Cancer 78 (1996) 2153-2156
74. Wong A., Musallam S., Tomlinson R., Shannon P., and Sharpe J. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 189 (2001) 71-81
75. Helmchen C., Rambold H., Sprenger A., Erdmann C., and Binkofski F. Cerebellar activation in opsoclonus: an fMRI study. Neurology 61 (2003) 412-415
76. Ridley A., Kennard C., Scholtz C., Buttner-Ennever J., Summers B., and Turnbull A. Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 110 (1987) 1699-1709
77. Wong A. An update on opsoclonus. Curr Opin Neurol 20 (2007) 25-31
78. Digre K. Opsoclonus in adults: report of three cases and review of the literature. Arch Neurol 43 (1986) 1165-1175
79. Luque F., Furneaux H., Ferziger R., et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 29 (1991) 241-251
80. Sutton I., Barnett M., Watson J., Ell J., and Dalmau J. Paraneoplastic brainstem encephalitis and anti-Ri antibodies. J Neurol 249 (2002) 1597-1598
81. Pittock S., Lucchinetti C., and Lennon V. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 53 (2003) 580-587
82. Blaes F., Fuhlhuber V., Korfei M., et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 58 (2005) 313-317
83. Korfei M., Fuhlhuber V., Schmidt-Woll T., Kaps M., Preissner K., and Blaes F. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol 170 (2005) 150-157
84. Pranzatelli M., Tate E., Travelstead A., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 28 (2006) 585-593
85. Mitchell W., Davalos-Gonzalez Y., Brumm V., et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 109 (2002) 86-98
86. Pranzatelli M., Tate E., Dukart W., Flint M., Hoffman M., and Oksa A. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 147 (2005) 372-378
87. Bataller L., Graus F., Saiz A., and Vilchez J. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124 (2001) 437-443
88. Erlich R., Morrison C., Kim B., Gilbert M., and Alrajab S. ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features-correlation of clinical improvement with tumor response. Cancer Invest 22 (2004) 257-261
89. Gultekin S., Rosenfeld M., Voltz R., Eichen J., Posner J., and Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123 (2000) 1481-1494
90. Lawn N., Westmoreland B., Kiely M., Lennon V., and Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 78 (2003) 1363-1368
91. Scheid R., Lincke T., Voltz R., von Cramon D., and Sabri O. Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol 61 (2004) 1785-1789
92. Ances B., Vitaliani R., Taylor R., et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128 (2005) 1764-1777
93. Graus F., Keime-Guibert F., Rene R., et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124 (2001) 1138-1148
94. Dalmau J., Graus F., Villarejo A., Posner J., Blumenthal D., Thiessen B., Saiz A., Meneses P., and Rosenfeld M. Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 (2004) 1831-1844
95. Antoine J., Honnorat J., Camdessanche J., et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 49 (2001) 214-221
96. Thieben M., Lennon V., Boeve B., Aksamit A., Keegan M., and Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62 (2004) 1177-1182
97. Tuzun E., and Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 13 (2007) 261-271
98. Bataller L., Kleopa K., Wu G., Rossi J., Rosenfeld M., and Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry 78 (2007) 381-385
99. Dalmau J., Graus F., Rosenblum M., and Posner J. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine 71 (1992) 59-72
100. Sillevis S., Grefkens J., De Leeuw B., et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 249 (2002) 745-753
101. Alamowitch S., Graus F., Uchuya M., Rene R., Bescansa E., and Delattre J. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 120 (1997) 923-928
102. Mut M., Schiff D., and Dalmau J. Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua. J Neurooncol 72 (2005) 63-66
103. Shavit Y., Graus F., Probst A., Rene R., and Steck A. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 45 (1999) 255-258
104. Kinirons P., O'Dwyer J., Connolly S., and Hutchinson M. Paraneoplastic limbic encephalitis presenting as lingual epilepsia partialis continua. J Neurol 253 (2006) 256-257
105. Fadul C., Stommel E., Dragnev K., Eskey C., and Dalmau J. Focal paraneoplastic limbic encephalitis presenting as orgasmic epilepsy. J Neurooncol 72 (2005) 195-198
106. Jacobs D., Fung K., Cook N., Schalepfer W., Goldberg H., and Stecker M. Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome. J Neurol Sci 213 (2003) 77-82
107. Antoine J., Honnorat J., Vocanson C., et al. Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retina. J Neurol Sci 117 (1993) 215-223
108. Vernino S., Tuite P., Adler C., et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 51 (2002) 625-630
109. Ducray F., Roos-Weil R., Garcia P., et al. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 78 (2007) 325-327
110. Antoine J., Honnorat J., Anterion C., et al. Limbic encephalitis and immunological perturbations in two patients with thymoma. J Neurol Neurosurg Psychiatry 58 (1995) 706-710
111. Muehlschlegel S., Okun M., Foote K., Coco D., Yachnis A., and Fernandez H. Paraneoplastic chorea with leukoencephalopathy presenting with obsessive-compulsive and behavioral disorder. Mov Disord 20 (2005) 1523-1527
112. Compta Y., Iranzo A., Santamaria J., Casamitjana R., and Graus F. REM sleep behavior disorder and narcoleptic features in anti-Ma2-associated encephalitis. Sleep 30 (2007) 767-769
113. Overeem S., Dalmau J., Bataller L., et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 62 (2004) 138-140
114. Matsumoto L., Yamamoto T., Higashihara M., et al. Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes. Mov Disord 22 (2007) 728-731
115. Castle J., Sakonju A., Dalmau J., and Newman-Toker D. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease. Nat Clin Pract Neurol 2 (2006) 566-572
116. Hoffmann L., Jarius S., Pellkofer H., et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: Twenty-two newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry (2008) 10.1136/jnnp.2007.118588 published online Jan 25.
117. Sahashi K., Sakai K., Mano K., and Hirose G. Anti-Ma2 antibody related paraneoplastic limbic/brain stem encephalitis associated with breast cancer expressing Ma1, Ma2, and Ma3 mRNAs. J Neurol Neurosurg Psychiatry 74 (2003) 1332-1335
118. Rojas-Marcos I., Graus F., Sanz G., Robledo A., and Diaz-Espejo C. Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: case study. Neuro-oncol 9 (2007) 75-77
119. Pruss H., Voltz R., Gelderblom H., et al. Spontaneous remission of anti-Ma associated paraneoplastic mesodiencephalic and brainstem encephalitis. J Neurol (2008) 10.1007/s00415-008-0573-8 published online Jan 20.
120. Iranzo A., Graus F., Clover L., et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol 59 (2006) 178-181
121. Jacob S., Irani S., Rajabally Y., et al. Hypothermia in VGKC antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry 79 (2008) 202-204
122. Kleopa K., Elman L., Lang B., Vincent A., and Scherer S. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 129 (2006) 1570-1584
123. Pozo-Rosich P., Clover L., Saiz A., Vincent A., and Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 54 (2003) 530-533
124. Jarius S., Hoffmann L., Clover L., Vincent A., and Voltz R. CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci (2007) 10.1016/j.jns.2007.11.004 published online Dec 6.
125. Majoie H., De Baets M., Renier W., Lang B., and Vincent A. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 71 (2006) 135-141
126. Antozzi C., Binelli S., Frassoni C., et al. Immunotherapy responsive startle with antibodies to voltage gated potassium channels. J Neurol Neurosurg Psychiatry 78 (2007) 1281-1290
127. Seki M., Suzuki S., Iizuka T., et al. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry 79 (2008) 324-326
128. Sansing L., Tuzun E., Ko M., Baccon J., Lynch D., and Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 3 (2007) 291-296
129. Iizuka T., Sakai F., Ide T., et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 70 (2008) 504-511
130. Shimazaki H., Ando Y., Nakano I., and Dalmau J. Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus. J Neurol Neurosurg Psychiatry 78 (2007) 324-325
131. Novillo-Lopez M., Rossi J., Dalmau J., and Masjuan J. Treatment-responsive subacute limbic encephalitis and NMDA receptor antibodies in a man. Neurology 70 (2008) 728-729
132. Takahashi Y., Mori H., Mishina M., et al. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua. Epilepsia 46 (2005) 152-158
133. Dambinova S., Khounteev G., Izykenova G., Zavolokov I., Ilyukhina A., and Skoromets A. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem 49 (2003) 1752-1762
134. Sabater L., Titulaer M., Saiz A., Verschuuren J., Gure A., and Graus F. SOX1 antibodies are markers of paraneoplastic Lambert Eaton myasthenic syndrome. Neurology (2007) 10.1212/01.wnl.0000281663.81079.24 published online Nov 21.
135. Zuliani L., Saiz A., Tavolato B., Giometto B., Vincent A., and Graus F. Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. J Neurol Neurosurg Psychiatry 78 (2007) 204-205
136. Vernino S., O'Neill B., Marks R., O'Fallon J., and Kimmel D. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 6 (2004) 55-62
137. Shams'ili S., de Beukelaar J., Gratama J., et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253 (2006) 16-20